![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
ABT-267 Combined With Pegylated Interferon Alpha-2a/ribavirin in Genotype 1 (GT1) HCV-Infected Treatment-Naïve
Subjects: 12-Week Antiviral and Safety Analysis
|
|
|
Reported by Jules Levin
EASL 2012 Apr 18-22 Barcelona Spain
J Greg Sullivan1, Maribel Rodriguez-Torres2, Eric Lawitz3, Fred Poordad4, Lino Rodrigues5, Andrew Campbell5, Carolyn Setze5, Wangang Xie5, Amit Khatri5, Emily Dumas5, Preethi Krishnan5, Tami Pilot-Matias5,
Laura Williams5, Barry Bernstein5
1Parkway Medical Center, Birmingham, Alabama, United States; 2Fundacion de Investigacion de Diego, San Juan, Puerto Rico; 3Alamo Medical Research, San Antonio, Texas, United States; 4Cedars-Sinai Medical Center, Los Angeles, California, United States, 5Abbott, Abbott Park, Illinois, United States
CONCLUSIONS
· ABT-267 + P/R was well tolerated with a safety profi le similar to P/R alone
· ABT-267 + P/R demonstrated potent antiviral activity with 86% of subjects achieving cEVR
(HCV RNA < LLOD) in GT1 HCV-infected treatment-naïve subjects
· These data support additional studies with ABT-267 in combination with other DAAs for the
treatment of chronic GT1 HCV infection
![EASL1.gif](../images/042512/042512-8/EASL1.gif)
![EASL2.gif](../images/042512/042512-8/EASL2.gif)
![EASL3.gif](../images/042512/042512-8/EASL3.gif)
![EASL4.gif](../images/042512/042512-8/EASL4.gif)
![EASL5.gif](../images/042512/042512-8/EASL5.gif)
![EASL6.gif](../images/042512/042512-8/EASL6.gif)
![EASL7.gif](../images/042512/042512-8/EASL7.gif)
![EASL8.gif](../images/042512/042512-8/EASL8.gif)
![EASL9.gif](../images/042512/042512-8/EASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|